🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Really important study looking at what-if scenarios about COVID-19 vaccination in Africa led by Yang 刘扬 with great input from Africa CDC and other colleagues!

Really important initiative by a brilliant group of modellers and other academics.

A successful GBS vaccine could create billions of $ in value and save 10,000s of lives each year, if prices allow equitable global access.

Our new paper “Estimating national-level measles case–fatality ratios in low-income and middle-income countries: an updated systematic review and modelling study” is out today in The Lancet Global Health thelancet.com/journals/langl…

The first paper for my PhD thesis is now available at The Lancet Global Health! 🎉 Our modelling shows that introducing new #TB #vaccines are likely to have a substantial health impact in LMICs 🗺️🦠💉 From LSHTM TB Modelling Group LSHTM TB Centre Vaccine Centre CMMID London School of Hygiene & Tropical Medicine thelancet.com/journals/langl…

Research by Waterlow et al. finds that next-generation vaccines may offer a cost-effective intervention to reduce influenza burden in low-income countries with year-round seasonality. London School of Hygiene & Tropical Medicine Naomi Waterlow Read more about this modelling study here: bmcmedicine.biomedcentral.com/articles/10.11…

1) In our recent review we introduce what are economic costs and why they are used in health economic studies Laura Downey Anna Vassall HITAP Mark Jit resource-allocation.biomedcentral.com/articles/10.11…

This new collection we put together shows most RSV burden is in very young infants in KE and ZA. So new RSV vaccines and mAbs could be even more cost-effective in some LMICs than recognised. Results of tremendous work by NICD Kenya Medical Research Institute PATH London School of Hygiene & Tropical Medicine investigators.

I'm delighted and humbled by this news. The award is really a testament to the dedication of my colleagues at LSHTM and around the world. I am so grateful for your support, encouragement and inspiration throughout my journey. Thank you!

Fantastic that The Economist are highlighting the global disparities around HPV vaccine uptake as well as the opportunity we have to end cervical cancer as public health problem.

Great that WHO's Full Value of Vaccines Assessment framework is now published in BMC Medicine . This has been used by WHO + collaborators to assess many recent vaccines in development. rdcu.be/df00V

SIAs reach more unvaccinated children but MCV2 is more efficient per dose at preventing measles cases. New VIMC DynaMICE measles modelling paper in The Lancet Global Health from Megan Auzenbergs, Han Fu and others in @cmmid exploring optimal vaccine strategies: sciencedirect.com/science/articl…

We are still far from reaching WHO's target of bringing HPV vaccines to 90% of girls before age 15. Excited by opportunities that 1-dose vaccine schedules offer to help bring HPV vaccines to more people. This paper led by Kiesha Prem is a key piece of evidence to inform this.

Thanks to co-authors Simon Procter, Edwin van Leeuwen, Sreejith Radhakrishnan, Mark Jit and Dr Roz Eggo! Also for a fuller understanding of the cost-effectiveness of such vaccines check out our other paper, answering similar questions in a completely different setting! bmcmedicine.biomedcentral.com/articles/10.11…

🆕 study in BMJ Global Health suggests introducing microarray patches into #immunisation programmes in LMICs could ⬇️ decrease #measles burden & prevent high treatment costs. Find out more 👇 bit.ly/3SENs32

Join #EUROGIN2024 for a pivotal session on 'One-Dose Vaccination: Evidence Gaps & Global Experiences' 💉Discuss dosing plans & advances in #hpvvaccine. with Mark Jit & Marc Brisson ow.ly/gvIX50Qj7Zx #hpvvirus #hpvcongress #hpvawareness #cervicalcancerawareness #Eurogin

We asked a range of key decision-makers what they need to know to about potential new vaccines The results were..... Alot, and WHO's Full Value of Vaccine Assessments framework helps But FVVAs could be even more useful Our new paper gives 3 ways FVVAs could be even better:

Vaccines saved 154 million lives over past 50 years study in The Lancet by World Health Organization (WHO) & LSHTM experts estimates. @MarkJit comments on the global success of the Expanded Programme on #Immunization (EPI) 🌍💉 More 👉bit.ly/4dzKt46